Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation

References

• Mardis ER, Ding L, Dooling DJ, et al., Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058–1066.
   PubMed Web of Science ®Google Scholar
• Kosmider O, Gelsi-Boyer V, Slama L, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia. 2010. DOI:10.1038/leu.2010.52.
   Web of Science ®Google Scholar
• Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, et al., Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18(6): 553–567.
   PubMed Web of Science ®Google Scholar
• Lu C, Ward PS, Kapoor GS, et al., IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483(7390):474–478.
   Web of Science ®Google Scholar
• Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012. DOI:10.1038/nature10866.
   Web of Science ®Google Scholar
• Losman JA, Looper RE, Koivunen P, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013;339(6127):1621–1625.
   PubMed Web of Science ®Google Scholar
• Chen C, Liu Y, Lu C, et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev. 2013. DOI:10.1101/gad.226613.113.
   Web of Science ®Google Scholar
• Kats LM, Reschke M, Taulli R, et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell. 2014. DOI:10.1016/j.stem.2013.12.016.
   PubMed Web of Science ®Google Scholar
• Kernytsky A, Wang F, Hansen E, et al. IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. Blood. 2015. DOI:10.1182/blood-2013-10-533604.
   PubMed Web of Science ®Google Scholar
• Fu X, Chin RM, Vergnes L, et al. 2-hydroxyglutarate inhibits ATP synthase and mTOR signaling. Cell Metab. 2015. DOI:10.1016/j.cmet.2015.06.009.
   Web of Science ®Google Scholar
• Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015. DOI:10.1038/nm.3788.
   Web of Science ®Google Scholar
• Wang F, Travins J, DeLaBarre B, et al., Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013;340(80): 622–626.
   Google Scholar
• Kats LM, Vervoort SJ, Cole R, et al. A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML. Leukemia. 2017;31(6):1466–1470.
   PubMed Web of Science ®Google Scholar
• Shih AH, Meydan C, Shank K, et al. Combination targeted therapy to disrupt aberrant oncogenic signaling and reverse epigenetic dysfunction in IDH2 and TET2 -mutant acute myeloid leukemia. Cancer Discov. 2017. DOI:10.1158/2159-8290.CD-16-1049.
   Web of Science ®Google Scholar
• Yen K, Travins J, Wang F, et al., AG-221, a First-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discov. 2017; 7(5): 478–493
   Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Pollyea DA, et al., Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017; 130(6): 722–731.
   Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Fathi AT, et al., Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019; 133(7): 676–687.
   Web of Science ®Google Scholar
• DiNardo CD, Stein EM, De Botton S, et al., Durable remissions with ivosidenib in IDH1 -mutated relapsed or refractory AML. N Engl J Med. 2018; 378(25): 2386–2398.
   PubMed Web of Science ®Google Scholar
• Yen KE, Bittinger MA, Su SM, et al. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene. 2010;29(49):6409–6417.
   PubMed Web of Science ®Google Scholar
• Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov. 2013;3(7):730–741.
   PubMed Web of Science ®Google Scholar
• Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 2010;102(13):932–941.
   PubMedGoogle Scholar
• Dang L, Su -S-SM. Isocitrate dehydrogenase mutation and (R)-2-hydroxyglutarate: from basic discovery to therapeutics development. Annu Rev Biochem. 2017. DOI:10.1146/annurev-biochem-061516-044732
   PubMed Web of Science ®Google Scholar
• Lee SM, Koh HJ, Park DC, et al. Cytosolic NADP+-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic Biol Med. 2002. DOI:10.1016/S0891-5849(02)00815-8.
   Web of Science ®Google Scholar
• Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010. DOI:10.1200/JCO.2010.28.3762.
   Web of Science ®Google Scholar
• Dang L, White DW, Gross S, et al., Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739–744.
   PubMed Web of Science ®Google Scholar
• Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010. DOI:10.1084/jem.20092506.
   Web of Science ®Google Scholar
• Ward PS, Patel J, Wise DR, et al., The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010; 17(3): 225–234.
   PubMed Web of Science ®Google Scholar
• Xu W, Yang H, Liu Y, et al., Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17–30.
   Web of Science ®Google Scholar
• Loenarz C, Schofield CJ. Expanding chemical biology of 2-oxoglutarate oxygenases. Nat Chem Biol. 2008;4(3):152–156.
   PubMed Web of Science ®Google Scholar
• Tsukada YI, Fang J, Erdjument-Bromage H, et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature. 2006;439(7078):811–816.
   PubMed Web of Science ®Google Scholar
• Kohli RM, Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature. 2013;502(7472):472–479.
   PubMed Web of Science ®Google Scholar
• demethylation and transcription. Nat Rev Mol Cell Biol. 2013.
   Web of Science ®Google Scholar
• Rasmussen KD, Helin K. Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev. 2016;30(7):733–750.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xiao M, Chen X, et al. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. Mol Cell. 2015 Feb 19;57(4):662–673.
   Google Scholar
• Koivunen P, Lee S, Duncan CG, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature. 2012. DOI:10.1038/nature10898.
   PubMed Web of Science ®Google Scholar
• Chowdhury R, Yeoh KK, Tian YM, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011. DOI:10.1038/embor.2011.43.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010. DOI:10.1016/j.ccr.2010.11.015.
   Web of Science ®Google Scholar
• Elkashef SM, Lin AP, Myers J, et al. IDH mutation, competitive inhibition of FTO, and RNA methylation. Cancer Cell. 2017;31(5):619–620.
   PubMed Web of Science ®Google Scholar
• Su R, Dong L, Li C, et al. R-2HG exhibits anti-tumor activity by targeting FTO/m6A/MYC/CEBPA signaling. Cell. 2018. DOI:10.1016/j.cell.2017.11.031.
   Google Scholar
• Lu C, Venneti S, Akalin A, et al. Induction of sarcomas by mutant IDH2. Genes Dev. 2013. DOI:10.1101/gad.226753.113.
   Web of Science ®Google Scholar
• Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013(80). DOI:10.1126/science.1236062.
   PubMedGoogle Scholar
• Chaturvedi A, Araujo Cruz MM, Jyotsana N, et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood. 2013. DOI:10.1182/blood-2013-03-491571.
   Web of Science ®Google Scholar
• Cairns RA, Iqbal J, Lemonnier F, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012. DOI:10.1182/blood-2011-11-391748.
   Google Scholar
• Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study. J Clin Oncol. 2010. DOI:10.1200/JCO.2009.27.3730.
   Web of Science ®Google Scholar
• Im AP, Sehgal AR, Carroll MP, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia. 2014;28(9):1774–1783.
   PubMed Web of Science ®Google Scholar
• Molenaar RJ, Thota S, Nagata Y, et al., Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia. 2015; 29(11): 2134–2142.
   PubMed Web of Science ®Google Scholar
• Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012. DOI:10.1016/j.cell.2012.06.023.
   PubMedGoogle Scholar
• Shlush LI. Age-related clonal hematopoiesis. Blood. 2018;131(5):496–504.
   PubMed Web of Science ®Google Scholar
• Shlush LI, Zandi S, Mitchell A, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014 Feb 20;506(7488):328–333.
   PubMed Web of Science ®Google Scholar
• Desai P, Mencia-Trinchant N, Savenkov O, et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat Med. 2018. DOI:10.1038/s41591-018-0081-z.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016. DOI:10.1056/NEJMoa1516192.
   Web of Science ®Google Scholar
• Rampal R, Alkalin A, Madzo J, et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep. 2014. DOI:10.1016/j.celrep.2014.11.004.
   PubMed Web of Science ®Google Scholar
• Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012. DOI:10.1056/NEJMoa1112304.
   Web of Science ®Google Scholar
• Abdel-Wahab O, Patel J, Levine RL. Clinical Implications of novel mutations in epigenetic modifiers in AML. Hematol Oncol Clin North Am. 2011;25(6):1119–1133.
   PubMed Web of Science ®Google Scholar
• Boissel N, Nibourel O, Renneville A, et al. Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood. 2011;117(13):3696–3697.
   PubMed Web of Science ®Google Scholar
• Green CL, Evans CM, Zhao L, et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood. 2011. DOI:10.1182/blood-2010-12-322479.
   Google Scholar
• Thol F, Damm F, Wagner K, et al. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood. 2010. DOI:10.1182/blood-2010-03-272146.
   PubMedGoogle Scholar
• Patnaik MM, Hanson CA, Hodnefield JM, et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: A mayo clinic study of 277 patients. Leukemia. 2012. DOI:10.1038/leu.2011.298.
   PubMedGoogle Scholar
• Heiblig M, Elhamri M, Nicolini FE, et al. Effect of initial body mass index on survival outcome of patients with acute leukemia: a single-center retrospective study. Clin Lymphoma Myeloma Leuk. 2015;15.
   Google Scholar
• Lin CC, Hou HA, Chou WC, et al. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution. Am J Hematol. 2014. DOI:10.1002/ajh.23596.
   Web of Science ®Google Scholar
• Lasho TL, Jimma T, Finke CM, et al. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood. 2012. DOI:10.1182/blood-2012-05-429696.
   Web of Science ®Google Scholar
• Amatangelo MD, Quek L, Shih A, et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017. DOI:10.1182/blood-2017-04-779447.
   PubMedGoogle Scholar
• Willekens C, Renneville A, Broutin S, et al. Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations. Leukemia. 2018. DOI:10.1038/s41375-018-0056-6.
   PubMed Web of Science ®Google Scholar
• Delahousse J, Verlingue L, Broutin S, et al. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase–mutated intrahepatic cholangiocarcinomas. Eur J Cancer. 2018;90:83–91.
   PubMed Web of Science ®Google Scholar
• Fathi AT, Sadrzadeh H, Borger DR, et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood. 2012. DOI:10.1182/blood-2012-06-438267.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Kohrt HE, Zhang B, et al. 2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. Leuk Lymphoma. 2013;54(2):408–410.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Propert KJ, Loren AW, et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood. 2013. DOI:10.1182/blood-2013-03-493197.
   Web of Science ®Google Scholar
• Janin M, Mylonas E, Saada V, et al., Serum 2-hydroxyglutarate production in IDH1 and IDH2 -mutated de novo acute myeloid leukemia: a study by the acute leukemia french association group. J Clin Oncol. 2014; 32(4): 297–305.
   PubMed Web of Science ®Google Scholar
• Borger DR, Goyal L, Yau T, et al. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res. 2014. DOI:10.1158/1078-0432.CCR-13-2649.
   Web of Science ®Google Scholar
• Brunner AM, Neuberg DS, Wander SA, et al. Use of 2HG levels in the serum, urine, or bone marrow to predict IDH mutations in adults with acute myeloid leukemia. Blood. 2015. DOI:10.1182/blood.V126.23.2597.2597.
   PubMedGoogle Scholar
• Lemonnier F, Cairns RA, Inoue S, et al. The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. Proc Natl Acad Sci USA. 2016. DOI:10.1073/pnas.1617929114.
   Web of Science ®Google Scholar
• Poinsignon V, Mercier L, Nakabayashi K, et al. Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications. J Chromatogr B Anal Technol Biomed Life Sci. 2016. DOI:10.1016/j.jchromb.2016.04.030.
   PubMed Web of Science ®Google Scholar
• Yen K, Travins J, Wang F, et al. AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discov. 2017;7(5):478–493.
   Web of Science ®Google Scholar
• Quek L, David MD, Kennedy A, et al., Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nat Med. 2018; 24(8): 1167–1177.
   PubMed Web of Science ®Google Scholar
• Dittakavi S, Jat RK, Mullangi R. Quantitative analysis of enasidenib in dried blood spots of mouse blood using an increased-sensitivity LC–MS/MS method: application to a pharmacokinetic study. Biomed Chromatogr. 2019. DOI:10.1002/bmc.4491
   Web of Science ®Google Scholar
• Dutta R, Zhang TY, Köhnke T, et al. Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2. J Clin Invest. 2020 Apr 1;130(4):1843–1849. DOI:10.1172/JCI133344.
   Web of Science ®Google Scholar
• Harding JJ, Lowery MA, Shih AH, et al. Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition. Cancer Discov. 2018. DOI:10.1158/2159-8290.CD-18-0877.
   Web of Science ®Google Scholar
• Intlekofer AM, Shih AH, Wang B, et al., Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature. 2018; 559(7712): 125–129.
   PubMed Web of Science ®Google Scholar
• Frankel SR, Eardley A, Lauwers G, et al. The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann Intern Med. 1992. DOI:10.7326/0003-4819-117-4-292
   Web of Science ®Google Scholar
• De Botton S, Dombret H, Sanz M, et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood. 1998. DOI:10.1182/blood.V92.8.2712.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Andersen JW, Schiffer CA, et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood. 2000 Jan 1;95(1):90–95.
   Web of Science ®Google Scholar
• Camacho LH, Soignet SL, Chanel S, et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol. 2000. DOI:10.1200/JCO.2000.18.13.2620.
   PubMed Web of Science ®Google Scholar
• Montesinos P, Sanz MA. The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature. Mediterr. J Hematol Infect Dis. 2011;3(1):e2011059.
   PubMedGoogle Scholar
• Fathi AT, DiNardo CD, Kline I, et al., Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2 analysis of a phase 1/2 study. JAMA Oncol. 2018; 4(8): 1106.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Tallman MS, de Botton S, et al., Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 2019; 33(11): 2575–2584.
   Web of Science ®Google Scholar
• Stein EM, Fathi AT, DiNardo CD, et al., Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 2020; 7(4): e309-e319.
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Fathi AT, et al. Ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation is safe, effective, and leads to MRD-negative complete remissions. Blood. 2018. DOI:10.1182/blood-2018-99-110449.
   Web of Science ®Google Scholar
• DiNardo CD, Schuh AC, Stein EM, et al. Enasidenib plus azacitidine significantly improves complete remission and overall response compared with azacitidine alone in patients with newly diagnosed acute myeloid leukemia (AML) with isocitrate dehydrogenase 2 (IDH2) mutations: interim phase Ii res. Blood. 2019. DOI:10.1182/blood-2019-130362.
   Web of Science ®Google Scholar
• Dinardo CD, Stein AS, Stein EM, et al. Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML). J Clin Oncol. 2018;36(15_suppl):7042.
   PubMed Web of Science ®Google Scholar